Genmab A/S (NASDAQ:GMAB) Downgraded to “Hold” Rating by Wall Street Zen

Genmab A/S (NASDAQ:GMAB) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued on Sunday.

Several other research firms have also recently weighed in on GMAB. HC Wainwright reissued a “buy” rating and issued a $37.00 price target (down previously from $50.00) on shares of Genmab A/S in a research note on Wednesday, April 9th. Truist Financial boosted their price target on shares of Genmab A/S from $45.00 to $46.00 and gave the company a “buy” rating in a research report on Tuesday, July 8th. Finally, Sanford C. Bernstein lowered shares of Genmab A/S from a “market perform” rating to an “underperform” rating in a research note on Tuesday, April 1st. One research analyst has rated the stock with a sell rating, four have given a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Genmab A/S presently has an average rating of “Moderate Buy” and a consensus target price of $37.80.

Genmab A/S Stock Down 0.6%

GMAB opened at $21.88 on Friday. Genmab A/S has a twelve month low of $17.24 and a twelve month high of $28.56. The company has a 50-day moving average price of $21.18 and a 200 day moving average price of $20.78. The company has a market cap of $14.04 billion, a PE ratio of 12.43, a price-to-earnings-growth ratio of 6.65 and a beta of 0.94.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.31 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.08. The firm had revenue of $715.00 million during the quarter, compared to the consensus estimate of $5.17 billion. Genmab A/S had a net margin of 35.11% and a return on equity of 18.08%. As a group, sell-side analysts expect that Genmab A/S will post 1.45 earnings per share for the current year.

Institutional Trading of Genmab A/S

Several institutional investors and hedge funds have recently modified their holdings of the business. Orbis Allan Gray Ltd increased its position in Genmab A/S by 102.8% during the first quarter. Orbis Allan Gray Ltd now owns 5,710,741 shares of the company’s stock worth $111,816,000 after purchasing an additional 2,895,179 shares during the last quarter. Deep Track Capital LP bought a new position in shares of Genmab A/S in the 4th quarter worth about $41,740,000. Renaissance Technologies LLC lifted its position in Genmab A/S by 7.8% in the 4th quarter. Renaissance Technologies LLC now owns 1,926,150 shares of the company’s stock valued at $40,199,000 after purchasing an additional 139,722 shares during the last quarter. Brandywine Global Investment Management LLC raised its position in shares of Genmab A/S by 6.0% during the 1st quarter. Brandywine Global Investment Management LLC now owns 1,717,397 shares of the company’s stock worth $33,627,000 after buying an additional 97,633 shares in the last quarter. Finally, Two Sigma Investments LP raised its position in shares of Genmab A/S by 122.2% during the 4th quarter. Two Sigma Investments LP now owns 1,706,364 shares of the company’s stock worth $35,612,000 after buying an additional 938,455 shares in the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.